Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Stock Information for Inhibikase Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
Inhibikase Announces Expansion of Senior Leadership Team
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.